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Abstract: Glaucoma management aims to preserve patients’ quality of life by halting progressive visual loss. Intraocular 
pressure reduction is the pivotal strategy: we establish a “target” pressure based on extent of visual damage, threat to 
visual performance, risk profile for further damage, pre-treatment pressure levels, family history and a patient’s life 
expectancy. Once an acceptable treatment regimen has been instituted, review ascertains whether damage has advanced 
and/or the risk of progressive damage has changed. Increased damage and/or increased risk of progressive damage suggest 
accelerated treatment, and lowered target pressures. 
When should management be stepped up? When a glaucoma patient, or a glaucoma suspect is getting worse and it 
matters, and when an individual is at increased risk of getting worse and it matters. 
At each review, the ophthalmologist seeks change in disease status: is it stable, uncertain whether or not it is stable, or 
progressing? Equally, the level of risk of further damage is assessed: is it unchanged, uncertain whether it is unchanged, 
or increased? If both disease status and risk are stable, the patient continues as is; if either or both have changed, treatment 
either can be initiated for suspects, or accelerated for patients. This means, intervene to reduce the perceived risk of 
further damage, and this means reducing or further reducing pressure. 
  Management of glaucoma is an ongoing challenge: the 
disease is incurable. It is usually progressive and the damage 
it causes is irreversible. In its early stages, symptoms are 
vague unless sought specifically [1], and presentation is 
often relatively late in the disease course [2]. The 
ophthalmologist’s goal is to maintain the patient’s Quality of 
Life. This is achieved by halting or at least slowing 
significantly further visual damage. Besides ensuring the 
patient’s general health status is optimal, intraocular pressure 
(IOP) reduction is the pivotal strategy – this is the only 
proven risk reduction treatment. 
  Inherent in this approach is the establishment of a 
“target” IOP level, guessed to be likely to ensure the 
patient’s visual security from further glaucomatous damage. 
Many factors are taken into account in setting a target IOP 
for a particular patient [3], including extent of visual damage 
already suffered, the threat of that damage to visual 
performance (such as proximity to fixation), the risk profile 
for further damage (such as presence of pseudoexfoliation 
syndrome), the pre-treatment IOP level, family history and 
the patient’s estimated life expectancy. Lowering IOP is not 
an end in itself, but a strategy to protect the individual 
patient from the threat of glaucoma-induced visual disability. 
  These same principles apply to patients who are 
“glaucoma suspects”: perceived to be at increased risk to 
develop glaucomatous visual damage but with no definitive 
signs of structural or functional damage at the time of   
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assessment. These include patients with ocular hypertension, 
glaucoma-like optic discs, and a family history of glaucoma, 
especially of blinding glaucoma. 
  Following ‘institution’ of an acceptable treatment 
regimen, the challenge is to review appropriately so as to 
ascertain whether or not further damage has occurred, and as 
to what is the ‘ongoing risk status’ for further damage. 
Management may need to be accelerated (“stepped up”) 
when the ophthalmologist identifies further damage or a 
change in the risk profile. Accelerating treatment means 
increasing efforts at IOP reduction, and/or resetting the 
target pressure. Therefore, these principles apply to 
glaucoma suspects being monitored to answer the question: 
does treatment need to be initiated? 
  When should management be stepped up? When a 
glaucoma patient or a glaucoma suspect is getting worse and 
it matters, and when such an individual is at increased risk of 
getting worse and it matters. 
  At each review, the ophthalmologist assesses any change 
in disease status: is it stable, uncertain whether or not it is 
stable, or progressing? Equally, the level of risk of further 
damage is assessed: is it unchanged, uncertain whether or not 
it is unchanged, or increased? (Table 1). If both disease 
status and risk are assessed as stable, the patient can continue 
as is; if either or both have changed, treatment either can be 
initiated for suspects, or “stepped up” for patients. This 
means, actively intervening to reduce the perceived risk of 
further damage, and this means reducing or further reducing 
IOP. 
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Table 1  Decision Square for Management of Glaucoma and 
Suspects [4] 
 
Disease Status 
Risk 
Stable Uncertain  Progressing 
Increased  + ++  +++ 
Uncertain  Reassess risk  Reassess risk & disease status  ++ 
Unchanged  -  Reassess disease status  + 
-   No  change  needed. 
+    Modest acceleration of management. 
++    Moderate acceleration of management. 
+++   Aggressive acceleration of management. 
 
  What are the risk factors? For onset of glaucomatous 
damage, they include older age, strong family history, higher 
IOP, glaucomatous damage in the contralateral eye, and 
lower central corneal thickness, pigment dispersion and 
pseudo-exfoliation syndromes as well as disc or disc margin 
haemorrhage, large cup-to-disc ratio (in the context of disc 
size), diabetes, and vasospastic syndromes like migraine and 
Raynaud’s phenomenon. For glaucoma progression, add to 
these lower ocular perfusion pressure (lower blood pressure) 
and more advanced damage at baseline (such as damage in 
both visual hemifields). 
  To tailor therapy appropriately for individual patients, it 
is helpful to consider risk categories [4]: 
1.  Glaucoma with a high 5-year risk for progression, or 
a high 5-year risk of visual disability, with a target 
IOP reduction of 40% or more from baseline [5-7], or 
1-2 standard deviations below the patient’s ethnic 
population mean (whichever is the lower), if the 
therapeutic index (potential benefit assessed against 
possible harm) justifies it. 
•  Moderate to advanced glaucoma damage with 
correlating structural and functional loss. 
•  Demonstrated progression – especially if over a 
short time. 
•  Higher IOP. 
•  Bilateral visual field loss. 
•  Field loss involving both superior and inferior 
hemifields. 
•  Field loss threatening fixation. 
•  Pigmentary and/or pseudo-exfoliation syndromes or 
other secondary glaucomas. 
•  Quality of life already affected by damage. 
•  Younger age patient with advanced damage. 
•  Angle-closure glaucoma. 
2.  Glaucoma with moderate 5-year risk for progression 
[8], or glaucoma suspect with high risk for conversion 
to glaucoma [9], with a target IOP reduction of 30% 
or more from baseline, or the population mean 
(whichever is the lower). 
•  Mild glaucomatous damage with correlating 
structural and functional loss and higher baseline 
IOP. 
•  Mild to moderate glaucomatous damage with lower 
baseline IOP. 
•  Primary angle-closure with peripheral anterior 
synechiae and high IOP. 
•  Younger age with damage. 
3.  Glaucoma suspect at moderate 5-year risk for 
damage, in whom “masterful inactivity” with 
monitoring for change is an option, as is a modest 
IOP reduction, depending on patient preferences and 
overall risk. Treat if risks increase (or damage 
identified) with a target IOP reduction of 20% or 
more from baseline, or 1 standard deviation above the 
population mean, whichever is the lower. The fellow 
eye might require the same target IOP depending on 
risk status. 
•  Fellow of eye with established damage, excluding 
unilateral secondary glaucoma. 
•  Ocular hypertension with multiple additional risk 
factors (thin central corneal thickness, higher IOP, 
glaucoma-like disc). 
•  Recurrent disc haemorrhages. 
•  Pseudo-exfoliation syndrome. 
•  Younger age. 
4.  Glaucoma suspect at lower risk for visual loss [10], in 
whom careful establishment of structural and 
functional baselines and appropriate review frequency 
will allow “masterly” monitoring. 
•  Ocular hypertension. 
•  Older age. 
•  Family history. 
•  Primary angle-closure suspect. 
•  Pigment dispersion syndrome with normal IOP. 
•  Glaucoma-like disc. 
•  A combination of risk factors of lesser importance 
including steroid responder, myopia, diabetes 
mellitus, systemic hypertension, uveitis. 
  What this implies is recognition of the parallel static and 
dynamic profiles we create and modify for each patient: 
static is the baseline assessment of any damage that exists. 
Dynamic is ongoing assessment of damage that exists 
(structural and/or functional) and the risk either of 
development (glaucoma suspects) or progression (glaucoma 
patients) of such damage. 
  Following dynamic re-assessment of a patient, the 
ophthalmologist has three choices. If status and risk are 
stable, offer reassurance and determine appropriate timing 
for the next review. If risk profile has changed (e.g. increase 
in IOP), opt for a “soft push”: trial an increase in therapy by 
switching or increasing medications or by offering laser 
trabeculoplasty. If damage and especially the risk of visual 
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treatment aggressively by adding medications and/or 
performing laser trabeculoplasty and/or considering surgery. 
Review needs to ensure that the increased measures have 
achieved their goals: reduction in risk of further damage and 
stabilization of damage. 
  An approach like this allows us as clinicians to determine 
a personalized therapeutic index: potential benefit of 
intervention for that patient, versus the possibility of causing 
harm. It allows us to involve the patient actively and 
meaningfully in his/her decision-making process at every 
step along the way. For a chronic, incurable, usually 
progressive disease causing irreversible damage, often 
asymptomatically, this is critical for management success in 
the longer-term. 
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